JP2023501590A5 - - Google Patents
Info
- Publication number
- JP2023501590A5 JP2023501590A5 JP2022527744A JP2022527744A JP2023501590A5 JP 2023501590 A5 JP2023501590 A5 JP 2023501590A5 JP 2022527744 A JP2022527744 A JP 2022527744A JP 2022527744 A JP2022527744 A JP 2022527744A JP 2023501590 A5 JP2023501590 A5 JP 2023501590A5
- Authority
- JP
- Japan
- Prior art keywords
- human patient
- pharmaceutical composition
- dose
- composition according
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934945P | 2019-11-13 | 2019-11-13 | |
| US62/934,945 | 2019-11-13 | ||
| US202063034510P | 2020-06-04 | 2020-06-04 | |
| US63/034,510 | 2020-06-04 | ||
| PCT/IB2020/060718 WO2021095009A1 (en) | 2019-11-13 | 2020-11-13 | Therapy for hematopoietic cell malignancies using genetically engineered t cells targeting cd70 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501590A JP2023501590A (ja) | 2023-01-18 |
| JP2023501590A5 true JP2023501590A5 (enExample) | 2023-11-06 |
Family
ID=73554470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527744A Pending JP2023501590A (ja) | 2019-11-13 | 2020-11-13 | Ｃｄ７０を標的化する遺伝子操作されたｔ細胞を使用する造血細胞悪性腫瘍のための療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220387571A1 (enExample) |
| EP (1) | EP4058051A1 (enExample) |
| JP (1) | JP2023501590A (enExample) |
| KR (1) | KR20220100912A (enExample) |
| CN (1) | CN114845730A (enExample) |
| AU (1) | AU2020384951A1 (enExample) |
| BR (1) | BR112022009290A2 (enExample) |
| CA (1) | CA3158090A1 (enExample) |
| IL (1) | IL292467A (enExample) |
| MX (1) | MX2022005815A (enExample) |
| WO (1) | WO2021095009A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| MX2022015586A (es) | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| US20220387488A1 (en) * | 2021-05-12 | 2022-12-08 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies |
| US20230128917A1 (en) * | 2021-09-14 | 2023-04-27 | Crispr Therapeutics Ag | Genetically engineered immune cells having a disrupted cd83 gene |
| CN117173092B (zh) * | 2023-06-28 | 2024-04-09 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种基于图像处理的鼻咽癌放疗方法及系统 |
| WO2025193386A1 (en) | 2024-03-13 | 2025-09-18 | Caribou Biosciences, Inc. | Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466291B2 (en) * | 2016-07-06 | 2022-10-11 | Cellectis | Sequential gene editing in primary immune cells |
| BR112019023608A2 (pt) * | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| MX2020008184A (es) * | 2018-02-01 | 2020-09-22 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70. |
| US20200063100A1 (en) * | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
-
2020
- 2020-11-13 BR BR112022009290A patent/BR112022009290A2/pt not_active Application Discontinuation
- 2020-11-13 JP JP2022527744A patent/JP2023501590A/ja active Pending
- 2020-11-13 EP EP20812137.6A patent/EP4058051A1/en not_active Withdrawn
- 2020-11-13 US US17/776,846 patent/US20220387571A1/en not_active Abandoned
- 2020-11-13 CN CN202080086735.4A patent/CN114845730A/zh active Pending
- 2020-11-13 KR KR1020227019519A patent/KR20220100912A/ko not_active Withdrawn
- 2020-11-13 IL IL292467A patent/IL292467A/en unknown
- 2020-11-13 WO PCT/IB2020/060718 patent/WO2021095009A1/en not_active Ceased
- 2020-11-13 MX MX2022005815A patent/MX2022005815A/es unknown
- 2020-11-13 CA CA3158090A patent/CA3158090A1/en active Pending
- 2020-11-13 AU AU2020384951A patent/AU2020384951A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lamb et al. | Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future | |
| US20240316062A1 (en) | Combination of immunotherapeutics and bisfluoroalkyl-1,4-benzodiazepinone compounds for treating cancer | |
| Kuzel et al. | Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma | |
| CN110475571B (zh) | 细胞免疫疗法前细胞毒性预调理的替代 | |
| JP2023501602A5 (enExample) | ||
| US20250090560A1 (en) | T cell receptors for immunotherapy | |
| US20220273722A1 (en) | Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment | |
| JP2023501611A5 (enExample) | ||
| CN111148514A (zh) | 与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂 | |
| Kawai et al. | Safety and efficacy of NY-ESO-1 antigen-specific T-cell receptor gene-transduced T lymphocytes in patients with synovial sarcoma: a phase I/II clinical trial | |
| CN110958881A (zh) | 与免疫调节剂联合应用于癌症免疫治疗的免疫调节性类视黄醇和rexinoid化合物 | |
| Xu et al. | Runx2 deficiency in osteoblasts promotes myeloma progression by altering the bone microenvironment at new bone sites | |
| JP2022531185A5 (enExample) | ||
| Miljkovic et al. | Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies | |
| Nicod et al. | CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans | |
| Cohen et al. | Tandem autologous–allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity | |
| US20240124608A1 (en) | Methods and materials for treating clonal t cell expansions | |
| US20060127502A1 (en) | Methods for inhibiting Stat3 signaling in immune cells | |
| Quéméneur et al. | Restriction of de novo nucleotide biosynthesis interferes with clonal expansion and differentiation into effector and memory CD8 T cells | |
| Inamoto et al. | A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation | |
| JPH08510131A (ja) | 癌およびウイルス性疾患を治療するための改変化ｔａｌｌ−１０４細胞の使用 | |
| Chen et al. | A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma | |
| US20030223998A1 (en) | Targeted immunotherapy of acute lymphoblastic leukemia (ALL) | |
| Cuntz et al. | of Acute Lymphoblastic Leukemia | |
| CN113769096A (zh) | 6-磷酸葡萄糖脱氢酶抑制剂的医药用途 |